Business

NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12

EDEN PRAIRIE, Minn., May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology

articleNeuroone Medical Technologies CorporationMay 3, 20223/company/neuroone-medical-technologies-corp/news/neurooner-to-report-second-quarter-fiscal-year-2022-financial-results-on-may-12
NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12

About this update from Neuroone Medical Technologies Corporation

[{"type":"text","content":"EDEN PRAIRIE, Minn., May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (\"NeuroOne\" or the \"Company\"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast Information:\nMay 12, 2022 – 4:30 PM Eastern Time\nParticipant Dial-In:877-407-8293 / +1 201-689-8349\nLive Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=MBrdTO6j\nPhone Replay: 877-660-6853 / +1 201-612-7415, Access ID: 13729644; available through May 26, 2022\nWebcast Replay: Available for 12 months\nAbout NeuroOne® Medical Technologies Corporation\nNeuroOne is a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. These solutions include electrodes that have the potential to reduce the number of hospitalizations, surgical procedures and cost while improving patient outcomes due to their potential for offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. A combination recording and RF ablation technology is currently under development. In addition, NeuroOne is currently testing its electrodes for long term stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning. Visit n1mtc.com.\n \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-report-second-quarter-fiscal-year-2022-financial-results-on-may-12-301538336.html\nSOURCE NeuroOne Medical Technologies Corporation","length":3652,"tagName":"div"}]

More updates from Neuroone Medical Technologies Corporation